CONCENTRA GROUP HOLDINGS PARENT, INC. (CON) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.62%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.62% | Share-based compensation / revenue. Period ending 2026-06-30. $14.20M ÷ $2.29B × 100 ≈ 0.62% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 2.29B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 374.81M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.29B | $14.20M | $374.81M | (m) | (m) | 0.62% | (m) | (m) |
| 2026-03-31 | (m) | $2.23B | $12.36M | $349.28M | (m) | (m) | 0.55% | (m) | (m) |
| 2025-12-31 | (m) | $2.16B | $10.49M | $333.99M | (m) | (m) | 0.48% | (m) | (m) |
| 2025-09-30 | (m) | $2.09B | $8.71M | $323.42M | (m) | (m) | 0.42% | (m) | (m) |
| 2025-06-30 | (m) | $2.01B | $6.55M | $315.18M | (m) | (m) | 0.33% | (m) | (m) |
| 2025-03-31 | (m) | $1.93B | $4.43M | $309.58M | (m) | (m) | 0.23% | (m) | (m) |
| 2024-12-31 | (m) | $1.90B | $2.33M | $304.76M | (m) | (m) | 0.12% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.84B | $651.00K | $287.63M | (m) | (m) | 0.04% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.72B | $2.14M | $258.53M | (m) | (m) | 0.12% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acadia Healthcare Company, Inc. (ACHC) | United States | $2.565B | -1.92 |